Amarin (AMRN) Slips as FDA Updates Orange Book
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Following Fifth NCE Delay, Amarin (AMRN) Has to Go-It-Alone on Vascepa - MKM
December 17, 2012 12:19 PM ESTMKM Partners commented on Amarin Corporation (NASDAQ: AMRN) Monday after the FDA's Oragle Book Cumulative Supplement for November once again didn't not show a ruling on NCE status for Vascepa. The firm notes this is the fifth delay to the NCE decision.
Based on yet another delay MKM's Jon LeCroy continue to assume that it is unlikely that Amarin will be able to successfully petition the FDA to... More
Amarin (AMRN) in Focus as Traders Await NCE Decision on Vascepa
December 14, 2012 1:07 PM ESTAmarin (Nasdaq: AMRN) shares are higher on the session as traders anticipate an NCE decision on Vascepa sometime today, though nothing is in stone.
Shares are 24 percent lower from the close on December 6th, with Amarin... More
